Print

Jennerex, Inc. to Present at the 14th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference  
2/8/2012 10:14:47 AM

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that Gregory Schafer, the company's chief financial officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference next week in New York City. The presentation is scheduled for Monday, February 13, 2012, at 4:30 p.m. ET.

This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation, go to the Company's website at www.jennerex.com and go to "Events." Please connect to the website at least 15 minutes prior to the event to allow for any software download that may be necessary. The archived webcast will be available for seven days following the presentation.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1 clinical trial in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

SOURCE Jennerex, Inc.